Tandem Diabetes Care (NSDQ:TNDM) announced today that it began the U.S. commercial launch of its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. In December, the San Diego-based company announced that the FDA cleared the t:slim X2 insulin pump and Control-IQ technology for controlling Type 1 diabetes, touting it as the first and […]
Abbott boosts support for Bigfoot Biomedical and its diabetes treatment tech
Diabetes treatment tech company Bigfoot Biomedical has raised another $45 million in the initial tranche of a Series C equity financing, with collaborator Abbott (NYSE:ABT) as the lead investor. “We are excited to announce Abbott’s deepening support of Bigfoot Biomedical with this Series C financing,” Bigfoot Biomedical CEO Jeffrey Brewer said in a news release today. […]
7 medtech advances to improve diabetes treatment
Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]
Tandem Diabetes Care appoints executive VP of strategy and corporate development
Tandem Diabetes Care (NSDQ:TNDM) this week said it appointed Elizabeth Gasser as executive VP of strategy and corporate development. Prior to joining the company, Gasser was an independent adviser for Tandem Diabetes Care. She has also led the corporate strategy function at Qualcomm and has held a number of leadership roles at Openwave Systems. “Liz has […]
Medtronic adds AI-fueled Klue to its diabetes management lineup
Medtronic (NYSE:MDT) said today it has completed the acquisition of Klue, a San Jose, Calif.-based software company that tracks people’s eating in real-time and analyzes it with artificial intelligence (AI) to help control diabetes. Medtronic plans to incorporate Klue’s technology into its Personalized Closed Loop (PCL) insulin pump system, which won FDA breakthrough device designation […]
Lilly to integrate DexCom CGMs in automated dosing system
Eli Lilly (NYSE:LLY) announced that it will integrate Dexcom (NSDQ:DXCM) products into its personalized diabetes management system, now under development. Under the new, non-exclusive agreement, Indianapolis-based Lilly will use San Diego-based Dexcom’s continuous glucose monitoring (CGM) devices in pen-based and pump-based platforms in Lily’s diabetes management system. The pen-based platform is designed to integrate personalized data from […]
Dexcom CEO apologizes for remote monitoring outage
Dexcom (NSDQ:DXCM) CEO Kevin Sayer publicly apologized on Friday for an outage over Thanksgiving weekend that cut off users’ ability to share glucose monitoring data with caregivers and loved ones. The Dexcom Follow app normally allows users of the company’s G6 continuous glucose monitor to share that data with up to 10 people, according to the […]
FDA approves Tandem Diabetes’ advanced hybrid closed-loop controller
The FDA today cleared the Tandem Diabetes Care (NSDQ:TNDM) t:slim X2 insulin pump and Control-IQ advanced hybrid closed-loop technology to control Type 1 diabetes. The agency also granted De Novo clearance to the Control-IQ device, which is compatible with a variety of continuous glucose monitors and insulin pumps. The t:slim system, which also includes the recently […]
Beta Bionics’ bionic pancreas wins breakthrough status from FDA
The FDA has granted Beta Bionics breakthrough device designation for its iLet bionic pancreas system. The designation provides Beta Bionics with priority FDA review. It covers all configurations of the device — insulin-only, glucagon-only, and bi-hormonal, including use with Zealand Pharma’s dasiglucagon, a glucagon analog in a ready-to-use aqueous solution, according to Boston-based Beta Bionics. […]
Dexcom warns of potential danger to European app users
Dexcom (NSDQ:DXCM) is warning European customers who have failed to updated the G6 iOS app for their G6 continuous glucose monitor that they may not receive scheduled alerts of high or low blood sugar. Failure to update to version 1.5.4 of the app may cause alarms and alerts from the G6 continuous glucose monitor to […]
- 1
- 2
- 3
- …
- 66
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn